Poolbeg Pharma (LON:POLB) Stock Price Up 2.9% – Here’s Why

Poolbeg Pharma PLC (LON:POLB)’s share price traded up 2.9% during mid-day trading on Wednesday . The company traded as high as GBX 7.18 and last traded at GBX 7.10. Approximately 301,551 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 1,622,017 shares. The stock had previously closed at GBX 6.90.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Tuesday, June 16th.

Poolbeg Pharma Stock Performance

The firm has a market capitalization of £49.36 million, a PE ratio of -7.45 and a beta of 1.81. The company’s fifty day moving average price is GBX 6.29 and its two-hundred day moving average price is GBX 5.05.

Poolbeg Pharma (LON:POLB) last released its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. On average, equities analysts expect that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.